Co-mutation of KRAS and the tumor suppressor LKB1, one of the most prevalent mutational combinations in lung tumor, is observed in about ~25% of KRAS-mutant lung adenocarcinomas (Skoulidis et al., 2015). The gene discussed is KRAS; the disease is lung adenocarcinoma.